Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMYT Amryt Pharma	$14.70 +0.1%	$14.64	$6.41 ▼ $14.77	$940.21M	0.84	757,360 shs	2.39 million shs
AURA Aura Biosciences	$6.10 -1.3%	$5.82	$4.35 ▼ $12.38	$306.65M	0.42	210,365 shs	158,942 shs
BMY Bristol Myers Squibb	$46.82 -0.9%	$48.35	$39.35 ▼ $63.33	$95.29B	0.38	12.97 million shs	15.85 million shs
OGN Organon & Co.	$9.89 +0.4%	$9.94	$8.01 ▼ $23.10	$2.57B	0.58	3.45 million shs	3.01 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMYT Amryt Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
AURA Aura Biosciences	-1.29%	-7.99%	+3.04%	-17.79%	-13.48%
BMY Bristol Myers Squibb	-0.90%	-6.59%	-0.84%	-22.47%	+14.71%
OGN Organon & Co.	+0.21%	-2.17%	+9.84%	-36.69%	-51.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	1.9636 of 5 stars	3.6	1.0	0.0	0.0	1.1	3.3	0.0
BMY Bristol Myers Squibb	4.9357 of 5 stars	3.2	5.0	4.2	4.0	2.9	3.3	1.3
OGN Organon & Co.	4.6862 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMYT Amryt Pharma	0.00	N/A	N/A	N/A
AURA Aura Biosciences	3.25	Buy	$22.00	260.66% Upside
BMY Bristol Myers Squibb	2.32	Hold	$58.00	23.87% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	82.08% Upside

Current Analyst Ratings Breakdown

Latest AURA, AMYT, BMY, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/25/2025	BMY Bristol Myers Squibb	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
4/25/2025	BMY Bristol Myers Squibb	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/23/2025	BMY Bristol Myers Squibb	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$70.00 ➝ $68.00
4/22/2025	BMY Bristol Myers Squibb	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$55.00 ➝ $55.00
4/22/2025	BMY Bristol Myers Squibb	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMYT Amryt Pharma	$222.54M	4.22	$0.98 per share	14.98	$5.58 per share	2.63
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
BMY Bristol Myers Squibb	$48.30B	1.97	$5.84 per share	8.02	$8.08 per share	5.79
OGN Organon & Co.	$6.40B	0.40	$4.94 per share	2.00	$1.83 per share	5.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMYT Amryt Pharma	$1M	-$0.06	N/A	735.00	N/A	-8.19%	1.70%	0.75%	N/A
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/8/2025 (Estimated)
BMY Bristol Myers Squibb	-$8.95B	$2.67	17.54	7.69	1.39	11.38%	87.62%	15.98%	7/31/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.43	2.64	1.03	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest AURA, AMYT, BMY, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion
4/24/2025	Q1 2025	BMY Bristol Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMYT Amryt Pharma	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
BMY Bristol Myers Squibb	$2.48	5.30%	N/A	92.88%	17 Years
OGN Organon & Co.	$0.08	0.81%	N/A	2.78%	N/A

Latest AURA, AMYT, BMY, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMYT Amryt Pharma	0.64	1.57	0.94
AURA Aura Biosciences	N/A	11.06	11.06
BMY Bristol Myers Squibb	2.65	1.28	1.17
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMYT Amryt Pharma	71.31%
AURA Aura Biosciences	96.75%
BMY Bristol Myers Squibb	76.41%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
AMYT Amryt Pharma	5.66%
AURA Aura Biosciences	5.40%
BMY Bristol Myers Squibb	0.09%
OGN Organon & Co.	1.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMYT Amryt Pharma	2,020	63.96 million	60.34 million	Not Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable

AURA, AMYT, BMY, and OGN Headlines

Recent News About These Companies

Investors who lost money on Organon & Co.(OGN) should contact The Gross Law Firm about pending Class Action - OGN

June 19 at 9:00 AM | prnewswire.com

ORGANON & CO. (NYSE: OGN) INVESTOR ALERT: Investors With Large Losses in Organon & Co. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

June 19 at 8:15 AM | globenewswire.com

Organon & Co. (NYSE:OGN) Given Average Rating of "Moderate Buy" by Brokerages

June 19 at 4:26 AM | marketbeat.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 18 at 11:40 PM | investing.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 18 at 10:48 PM | globenewswire.com

ROSEN, A RANKED AND LEADING FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

June 18 at 6:26 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN

June 18 at 11:14 AM | globenewswire.com

July 22, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against OGN

June 18 at 9:26 AM | globenewswire.com

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

June 18 at 8:38 AM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

June 18 at 7:28 AM | globenewswire.com

Exchange Traded Concepts LLC Raises Stock Holdings in Organon & Co. (NYSE:OGN)

June 18 at 3:58 AM | marketbeat.com

Organon: A Look Beyond The Dividend Cut

June 18 at 2:00 AM | seekingalpha.com

ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 17 at 10:13 PM | globenewswire.com

All You Need to Know About Organon (OGN) Rating Upgrade to Buy

June 17 at 1:00 PM | zacks.com

OGN or DOCS: Which Is the Better Value Stock Right Now?

June 17 at 12:41 PM | zacks.com

Organon: Persistent Headwinds Make This A Hold

June 17 at 11:03 AM | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

June 17 at 10:00 AM | prnewswire.com

Did You Lose Money on Organon & Co. (OGN)? Levi & Korsinsky Urges Investors to Act Before July 22, 2025

June 17 at 7:40 AM | accessnewswire.com

OGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Shareholders Have Opportunity to Lead Class Action Lawsuit!

June 17 at 7:00 AM | accessnewswire.com

Investors who lost money on Organon & Co.(OGN) should contact Levi & Korsinsky about pending Class Action - OGN

June 17 at 5:45 AM | prnewswire.com

GAMMA Investing LLC Has $1.02 Million Position in Organon & Co. (NYSE:OGN)

June 17 at 3:02 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA, AMYT, BMY, and OGN Company Descriptions

Amryt Pharma NASDAQ:AMYT

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Aura Biosciences NASDAQ:AURA

$6.10 -0.08 (-1.29%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$6.10 +0.01 (+0.08%)

As of 06/18/2025 04:04 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Bristol Myers Squibb NYSE:BMY

$46.82 -0.41 (-0.86%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$46.91 +0.09 (+0.19%)

As of 06/18/2025 07:57 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Organon & Co. NYSE:OGN

$9.89 +0.04 (+0.37%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$9.85 -0.04 (-0.41%)

As of 06/18/2025 07:59 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time